Concepedia

Fanying Meng

FM

Statistics

Publications

32

Citations

1.1K

H-Index

21

Active since

2007

Affiliations

Threshold Pharmaceuticals (United States)(Current)

Chinese Academy of Medical Sciences & Peking Union Medical College

Yunnan University

Hunan University of Traditional Chinese Medicine

Yunnan University of Traditional Chinese Medicine

Fanying Meng is an author at Threshold Pharmaceuticals (United States) specializing in medicine, pharmacology, and cancer pharmacology.

Publications per year

2007–2025

32

Publications

32

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

Fanying Meng, James Evans, Deepthi Bhupathi et al. · Molecular Cancer Therapeutics · 2011 · 206 citations

Medicine, Medicinal Chemistry, Pharmacology +17

OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL

Kathryn Evans, Tara Pritchard, Connor Jones et al. · Clinical Cancer Research · 2019 · 53 citations · Full text

Medicine, Oncology, Pharmacology +11

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia et al. · Cancer Biology & Therapy · 2015 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17

Potent Antitubulin Tumor Cell Cytotoxins Based on 3-Aroyl Indazoles

Xiaohong Cai, Fanying Meng, Charles P. Hart et al. · Journal of Medicinal Chemistry · 2007 · 50 citations

Medicine, Medicinal Chemistry, Pharmacology +15

SIRT1 Disruption in Human Fetal Hepatocytes Leads to Increased Accumulation of Glucose and Lipids

Takamasa Tobita, Jorge Guzman‐Lepe, Kazuki Takeishi et al. · PLoS ONE · 2016 · 47 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

1–5 of 32